Reporting of cluster randomised crossover trials 2023: extension of the CONSORT 2010 statement with explanation and elaboration — Joanne E. McKenzie (2024) | RDL Network
Reporting of cluster randomised crossover trials 2023: extension of the CONSORT 2010 statement with explanation and elaboration
Preprint 2024 en
Authors
JM
Joanne E. McKenzie
MT
Monica Taljaard
KH
Karla Hemming
Abstract
1 min read
In this report we present the Consolidated Standards of Reporting Trials (CONSORT) extension for the cluster randomised crossover (CRXO) trial. A CRXO trial involves randomisation of groups of individuals (‘clusters’) to different sequences of treatments over time. The design has gained popularity in settings where cluster randomisation is required as it can largely overcome the loss in power due to clustering in parallel cluster trials. However, the design has many methodological complexities, requiring tailored reporting guidance. The guideline was developed using a survey and in-person consensus meeting, informed by a systematic review examining the quality of reporting in CRXO trials and relevant CONSORT statements for individual, crossover, cluster and stepped-wedge designs. We provide recommended reporting items, along with explanations and examples.
Joanne E. McKenzie, Monica Taljaard, Karla Hemming, Sarah Arnup, Bruno Giraudeau, Sandra Eldridge, Richard Hooper, Brennan C Kahan, Tianjing Li, David Moher, Elizabeth L. Turner, Jeremy Grimshaw, Andrew Forbes
Linda Kwakkenbos, Mahrukh Imran, Stephen J. McCall, Kimberly A McCord, Ole Frøbert, Lars G. Hemkens, Merrick Zwarenstein, Clare Relton, Danielle B. Rice, Sinéad Langan, Eric I Benchimol, Lehana Thabane, Marion Campbell, Margaret Sampson, David Erlinge, Helena M. Verkooijen, David Moher, Isabelle Boutron, Philippe Ravaud, Jon Nicholl, Rudolf Uher, Maureen Sauvé, John Fletcher, David Torgerson, Chris Gale, Edmund Juszczak, Brett D. Thombs
Discussion(0)
No comments yet. Be the first to comment.